223 related articles for article (PubMed ID: 37298997)
21. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
22. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
23. Ataxia telangiectasia and Rad3-related (ATR) inhibition by VE-822 potently reversed 5-flourouracil resistance in colorectal cancer cells through targeting DNA damage response.
Mihanfar A; Asghari F; Majidinia M
Mol Biol Rep; 2024 Mar; 51(1):474. PubMed ID: 38553623
[TBL] [Abstract][Full Text] [Related]
24. DNA-PKcs, ATM, and ATR Interplay Maintains Genome Integrity during Neurogenesis.
Enriquez-Rios V; Dumitrache LC; Downing SM; Li Y; Brown EJ; Russell HR; McKinnon PJ
J Neurosci; 2017 Jan; 37(4):893-905. PubMed ID: 28123024
[TBL] [Abstract][Full Text] [Related]
25. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
[TBL] [Abstract][Full Text] [Related]
26. The role of NBS1 in the modulation of PIKK family proteins ATM and ATR in the cellular response to DNA damage.
Zhou J; Lim CU; Li JJ; Cai L; Zhang Y
Cancer Lett; 2006 Nov; 243(1):9-15. PubMed ID: 16530324
[TBL] [Abstract][Full Text] [Related]
27. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract][Full Text] [Related]
28. ATM loss disrupts the autophagy-lysosomal pathway.
Cheng A; Tse KH; Chow HM; Gan Y; Song X; Ma F; Qian YXY; She W; Herrup K
Autophagy; 2021 Aug; 17(8):1998-2010. PubMed ID: 32757690
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
30. 2-Mercaptoethanol protects against DNA double-strand breaks after kidney ischemia and reperfusion injury through GPX4 upregulation.
Moon D; Padanilam BJ; Jang HS; Kim J
Pharmacol Rep; 2022 Oct; 74(5):1041-1053. PubMed ID: 35989399
[TBL] [Abstract][Full Text] [Related]
31. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
32. RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.
Roulston A; Zimmermann M; Papp R; Skeldon A; Pellerin C; Dumas-Bérube É; Dumais V; Dorich S; Fader LD; Fournier S; Li L; Leclaire ME; Yin SY; Chefson A; Alam H; Yang W; Fugère-Desjardins C; Vignini-Hammond S; Skorey K; Mulani A; Rimkunas V; Veloso A; Hamel M; Stocco R; Mamane Y; Li Z; Young JTF; Zinda M; Black WC
Mol Cancer Ther; 2022 Feb; 21(2):245-256. PubMed ID: 34911817
[TBL] [Abstract][Full Text] [Related]
33. Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design.
Qi Y; Wang K; Long B; Yue H; Wu Y; Yang D; Tong M; Shi X; Hou Y; Zhao Y
Eur J Med Chem; 2023 Jan; 246():114945. PubMed ID: 36462444
[TBL] [Abstract][Full Text] [Related]
34. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
Zhou Y; Börcsök J; Adib E; Kamran SC; Neil AJ; Stawiski K; Freeman D; Stormoen DR; Sztupinszki Z; Samant A; Nassar A; Bekele RT; Hanlon T; Valentine H; Epstein I; Sharma B; Felt K; Abbosh P; Wu CL; Efstathiou JA; Miyamoto DT; Anderson W; Szallasi Z; Mouw KW
Sci Adv; 2023 Nov; 9(47):eadg2263. PubMed ID: 37992168
[TBL] [Abstract][Full Text] [Related]
35. Disease severity in a mouse model of ataxia telangiectasia is modulated by the DNA damage checkpoint gene Hus1.
Balmus G; Zhu M; Mukherjee S; Lyndaker AM; Hume KR; Lee J; Riccio ML; Reeves AP; Sutter NB; Noden DM; Peters RM; Weiss RS
Hum Mol Genet; 2012 Aug; 21(15):3408-20. PubMed ID: 22575700
[TBL] [Abstract][Full Text] [Related]
36. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury A; Hall S; Curtin N; Drew Y
Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
[TBL] [Abstract][Full Text] [Related]
37. IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.
O'Flanagan CH; O'Shea S; Lyons A; Fogarty FM; McCabe N; Kennedy RD; O'Connor R
Oncotarget; 2016 Aug; 7(35):56826-56841. PubMed ID: 27472395
[TBL] [Abstract][Full Text] [Related]
38. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
[TBL] [Abstract][Full Text] [Related]
39. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
40. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]